Provider fact sheet · dataset v2026.08.14-4 · last touched —
Embody: GLP-1 programs, prices, and verification status (2026)
Embody is a unverified entry in our universe. GLP-1 Watchdog's #1 pick at an advertised $69/month intro (semaglutide) — a figure we treat as an intro until renewal terms are verified, since it arrived wrapped in countdown timers.
Programs and pricing, in plain sentences
Compounded tirzepatide, flat plan — status: third-party reported. $129/mo month-to-month, $119/mo on 12-month prepay (new-customer terms effective July 2026; corroborated by a live-landing capture and a terms-sourced review). Semaglutide $79/$69 on the same structure. Renewal, refund, and cancellation terms carry logged conflicts — confirm at checkout and screenshot everything.
Every figure above carries its status — operator claims come from the provider, reported from third parties we cite, verified only after our own checkout walk. Machine-readable version: providers.json.
Update — August 14, 2026: Repriced and upgraded to third-party reported. Two corroborating recent sources — a live-landing capture (Jul 31) and a terms-sourced review — put new-customer pricing at $119–129/mo tirzepatide ($119 on 12-month prepay) and $69–79/mo semaglutide, effective July 2026, replacing the $349/$299 rates a competitor's dated checkout captures recorded into late July. Caveats logged: three repricings this summer, conflicting cancellation windows on Embody's own pages (72 hours vs five days), reported Trustpilot near 3.1–3.6 with refund complaints, operator Modern Metabolic Medicine (which runs twin brand SnagRx), service in 48 states (not MS/LA), and an oral tirzepatide gum product carrying the same no-human-absorption-data problem as every unproven oral format.
Verification status and open items
Current status: unverified, last touched —. Open verification items: dispensing pharmacy identity, state coverage map, cancellation terms. Source on file: universe scan. Corrections land within 48 hours via the public log — if your checkout contradicts this page, that report changes the dataset.
How Embody fits the market
GLP-1 Watchdog's #1 pick at an advertised $69/month intro (semaglutide) — a figure we treat as an intro until renewal terms are verified, since it arrived wrapped in countdown timers. Separately, a July 2026 Reddit thread reports a flat $129/month tirzepatide rate holding in practice. Both claims are logged with sources; neither is verified. Where it lands overall: the price ladder, the category winners, and the program finder all compute from the same dataset this page renders.
Advertising disclosure: outbound provider links may be commission-bearing; our partner relationship with NexLife is disclosed on the ownership page and never alters statuses or rankings.